🚀 VC round data is live in beta, check it out!
2cureX Valuation Multiples
Discover revenue and EBITDA valuation multiples for 2cureX and similar public comparables like Integragen, Epigenomics, Ludwig Enterprises, Mainz Biomed and more.
2cureX Overview
About 2cureX
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
Founded
2006
HQ
Employees
0
Website
Financials (FY)
EV
$3M
2cureX Financials
2cureX reported last fiscal year revenue of — and negative EBITDA of ($497K).
In the same fiscal year, 2cureX generated ($497K) in EBITDA losses and had net loss of ($497K).
2cureX P&L
In the most recent fiscal year, 2cureX reported revenue of — and EBITDA of ($497K).
2cureX expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($497K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($497K) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
2cureX Stock Performance
2cureX has current market cap of $3M, and enterprise value of $3M.
Market Cap Evolution
2cureX's stock price is $0.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3M | $3M | 0.3% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial2cureX Valuation Multiples
2cureX trades at (5.5x) EV/EBITDA.
2cureX Financial Valuation Multiples
As of April 19, 2026, 2cureX has market cap of $3M and EV of $3M.
Equity research analysts estimate 2cureX's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
2cureX has a P/E ratio of (6.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (4.8x) | XXX | XXX | XXX |
| P/E | — | XXX | (6.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 2cureX Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
2cureX Margins & Growth Rates
2cureX's revenue in the last fiscal year declined by (100%).
2cureX Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (87%) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
2cureX Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| 2cureX | XXX | XXX | XXX | XXX | XXX | XXX |
| Integragen | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ludwig Enterprises | XXX | XXX | XXX | XXX | XXX | XXX |
| Mainz Biomed | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagonal Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
2cureX M&A Activity
2cureX acquired XXX companies to date.
Last acquisition by 2cureX was on XXXXXXXX, XXXXX. 2cureX acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by 2cureX
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free Trial2cureX Investment Activity
2cureX invested in XXX companies to date.
2cureX made its latest investment on XXXXXXXX, XXXXX. 2cureX invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by 2cureX
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 2cureX
| When was 2cureX founded? | 2cureX was founded in 2006. |
| Where is 2cureX headquartered? | 2cureX is headquartered in Sweden. |
| How many employees does 2cureX have? | As of today, 2cureX has over 0 employees. |
| Is 2cureX publicly listed? | Yes, 2cureX is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of 2cureX? | 2cureX trades under 2CUREX ticker. |
| When did 2cureX go public? | 2cureX went public in 2017. |
| Who are competitors of 2cureX? | 2cureX main competitors are Integragen, Epigenomics, Ludwig Enterprises, Mainz Biomed. |
| What is the current market cap of 2cureX? | 2cureX's current market cap is $3M. |
| Is 2cureX profitable? | No, 2cureX is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.